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R

ace is becoming an increasingly common
lens through which biomedical researchers are studying the relevance of genes to
group predispositions that may affect disease susceptibility and drug response. These investigations contravene decades of research in the natural and social sciences demonstrating that social
categories of race have little genetic significance. 1
Nevertheless, a resounding debate has ensued over
the utility of race in biomedical research — particularly as new drugs claiming to serve particular racial populations enter the marketplace. Now
that the Food and Drug Administration (FDA) has
approved BiDil as the first race-specific treatment
despite conflicting evidence and unsettled debates,
is there a way for federal regulators to promote
research that may address minority health concerns without giving undue credence to the dangerous idea that social understandings of race are
genetically relevant? It may be useful for the FDA
to turn to an area with experience negotiating such
dilemmas — constitutional law — and its approach
— strict scrutiny — to help guide when and under
which circumstances government should give effect
to racial categories in biomedicine.

Controversy over the Relevance of Race to
Biomedical Research
Much of the 20th century’s struggles around race
involved challenging the problematic link often made
between social categories of race and presumptions
surrounding groups’ heritable predispositions. Yet new
research looking at the genetic underpinnings of disease, health outcomes, and drug response is rethinking
this approach, giving renewed credence to arguments
suggesting that social categories of race reflect meaningful genetic differences. Though there is considerable evidence demonstrating the social determinants
that give rise to racial disparities in health outcomes,2
research using race as a proxy for groups’ biological
predispositions is becoming a remarkable trend at the
intersection of population genetics and biomedical
research. Some argue this will dramatically reshape
clinical interactions and health care delivery.3
This has stirred a heated debate in scientific and bioethical communities over when and how race should
be used in biomedical research. Those supporting the
use of race and ancestral background point to at least
three sets of studies in population genetics that ostenOsagie K. Obasogie, J.D., is an Associate Professor of Law
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sibly show significant genetic variation both within
racial and ethnic subpopulations and among the five
main racial groups defined by continental ancestry.4
First, population genetic data from indigenous groups
have enabled researchers to construct ancestral tree
diagrams that presumptively show that human genetic
diversity can be apportioned along five major branches
that roughly correspond to the five main continents.5
Second, multi-locus genetic data and cluster analyses have resulted in genetic delineations that roughly
map onto self-identified racial groups and continental
ancestry.6 Third, researchers have shown that alleles
(genetic variants) with a frequency of 20% or more
in one racial group are likely to appear in others, but
alleles appearing less frequently are more likely to be
contained within the racial group.7 Since Africans have
greater genetic variability but more low-frequency
alleles, race-specific genetic variants are deemed to be
more common among this group. This “indicate[s]
that the frequency of variant alleles underlying disease
or normal phenotypes can vary substantially among
racial groups, leading to differences in the frequency
of the phenotype themselves.”8
While these studies give the appearance of a correlation between certain genes and social categories
of race, there has been a growing critique concerning
how these studies might reify rather than reveal race
as a genetic category. Evolutionary geneticist James
L. Graves has pointed out how physical anthropologists and geneticists have repeatedly demonstrated the
principle of discordance since the 1940s: that populations’ physical features and genetic variations do not
consistently correlate with one another. Graves notes
that “if one attempts to take multiple physical characters to define racial groups, you arrive at categorizations that are not indicative of their evolutionary
history.”9 And, in a related critique, physical anthropologist Deborah Bolnick has raised important questions concerning the methods used to infer individual
ancestry from genetic data — methods that are also
used to support arguments that social understandings
of race are reflected in populations’ underlying genetic
structures.10 With regards to two oft-cited articles
by Noah Rosenburg et al. and Michael Bamshad et
al. that use the computer program structure to identify genetic clusters that correspond with geographic
origin, Bolnick shows how the evidence for genetic
clustering around ancestry does not arise organically
out of the data but depends heavily upon a series of
questionable assumptions — both from the underlying program and its users.11
Others have also raised serious doubts as to whether
race, as a social category, is significant to genomic
research. Racially targeted therapies are based upon
492

the presumption that the frequencies of alleles that
influence drug efficacy are meaningfully and predictably different for each race. The science supporting
this conclusion, however, is far from conclusive. For
example, where microsatellite loci have been used to
ground classifications that approximate continental
groups, the results have been questioned:
[It] depends in part on the cumulative effect of
minor differences in the frequencies of common
alleles and in part on the effect of population
specific alleles. In neither case is it apparent
that such differences have relevance for traits
that are important to health. Most populationspecific microsatellite alleles are unlikely to be
functional; rather, like a last name, they merely
help to verify the geographic origin of a person’s
ancestry.12
Moreover, some have argued that allele frequency may
not be particularly relevant to pursuing a genetic basis
for racial categorizations in biomedical sciences. Using
allele frequencies to categorize people is arguably “not
the same as apportioning the whole of human diversity
into medically relevant categories. The more germane
outcome — that the sets of common functional polymorphisms are distributed in discrete racial categories — has not been demonstrated.”13 Most population
geneticists continue to agree that the vast majority of
all genetic variation occurs within continental populations, not between them.14
Those who question the utility of race to genomic
research are not only troubled by what they perceive to
be inconclusive and unpersuasive science, but also by
the social harms that may result when social categories of race are prematurely accepted as reflecting real
genetic divisions among humans. What is particularly
troublesome for these commentators is the extent to
which minorities in general, and African Americans
in particular, are assumed to be genetically predisposed to a remarkably high number of chronic diseases when little genetic data has been systematically
analyzed and various social and environmental factors
remain inextricably intertwined. To many, the recent
trend within the biomedical sciences to demonstrate
how blacks are genetically predisposed to adverse
health outcomes creates conditions where society
stops looking at the often discriminatory environmental and structural conditions that strongly correlate
with these health disparities. Troy Duster notes that
using social categories such as race as an explanatory
proxy for genetic differences in health outcomes creates a “complex feedback loop and interaction effect
between phenotype and social practices related to that
journal of law, medicine & ethics
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phenotype…[that is] poised to exert a cascading effect
— resinscribing taxonomies of race across a broad
range of scientific practices and fields.”15
These debates are as robust as any contemporary
discussion in the biomedical sciences. Any reasonable, science-driven resolution or consensus will
require decades of clinical research supported by millions of dollars. In the meantime, it is not enough to
say that this research should categorically stop given
the explosive nature of this conversation; not pursuing
race-based medicines may leave the most vulnerable
populations without life-saving or life-improving medications. On the other hand, it is similarly important
to grapple with the gruesome historical relationship
science has had with race and, in particular, the real
threat to minority communities when their adverse
social or health outcomes are discussed as a function
of who they are.

The circumstantial evidence supporting BiDil’s
race specific claims may be persuasive to some but is
far from conclusive. Though BiDil, a pill containing
hydralazine and isosorbide dinitrate, had been tested
in two earlier clinical trials (V-HeFT I and V-HeFT
II), its FDA approval was propelled in large part by
the African-American Heart Failure Trial (A-HeFT).
This trial only enrolled patients that self-identified as
Black16 — an unorthodox decision “based on observations of differences in prevalence, risk, profiles, causation, disease severity, outcomes, and response to therapy between black patients and white patients with
heart failure.”17 Though social scientists question the
methodological soundness of research findings relying
solely on self-identified race,18 the A-HeFT researchers found the trial results to be promising: the placebo
group experienced a significantly higher mortality
rate and lower quality of life than patients using BiDil,

Steven Nissen noted that the committee “us[ed] self-identified race as a
surrogate for genomics” when they advised the FDA to approve BiDil’s racespecific indication. This is only one example of how race as an entrée to
personalized medicines is becoming an increasingly important consideration
for federal regulators and why the FDA should prepare for what many predict
will be nothing short of a revolution in how we approach health care.
The Emerging Racial Pharmacy
In the midst of these debates, the bricks and mortar
of the racial pharmacy are being put into place. BiDil,
a drug patented and marketed by NitroMed to treat
African American heart failure, arrived on the scene
in June 2005 as the first drug to receive FDA approval
for treating a specific racial group.
BiDil has been widely cited as exemplifying a breakthrough in personalized medicine. Though not a pharmacogenomic product per se, BiDil lends credibility
to race based genomic research by advancing the logic
that it is indeed possible, if not preferable, to use race
as a presumptively genetic marker to segment drug
markets. As the first drug patented as race-specific
(a legal claim about race and genetics), the first to be
approved by the federal government as race-specific
(a state claim about race and genetics) and the first to
be marketed as race specific (an economic claim about
race and genetics), BiDil represents a remarkable step
forward in giving credence to the idea that social categories of race can be an appropriate proxy for yet to be
known genes that are both unique to particular racial
groups and the cause of specific health outcomes.

suggesting that BiDil works differently in Blacks than
other groups. Nonetheless, many have raised serious concerns as to whether a clinical trial that only
included blacks can show, as a matter of science, that
they respond differently to a drug than other racial
groups.
A central concern here is as much about how people
think about race and racial disparities as it is about
particular health outcomes. BiDil’s ostensible effectiveness notwithstanding, the logic underpinning its
arrival worries many — particularly in the context of
inconclusive research over the utility of race as a predictive category for drug response. Health care practices that fixate on molecular and genetic differences
as an explanation for racial disparities in health may
prematurely deflect attention from known social determinants of health: economic class, social conditions,
and environmental factors among others. Allowing
markets to move this discussion to local pharmacies
before scientists can come to some reasonable consensus may be premature; some blacks with heart
failure may individually benefit from BiDil, but the
black community as a whole may suffer if this leads to

race, pharmaceuticals, and medical technology • fall 2008

493

S Y MPO SIUM

an uncritical acceptance that resuscitates the dangerous idea that differences in phenotype, their adherent
social meanings, and racial disparities in health outcomes are observable at a molecular level.
Commentaries on BiDil and the future of race-specific medicines have been predictably heated. Some
proponents of race-based therapies concede that race
is an imprecise if not crude marker for understanding
genetic variance, yet ultimately find it to be a useful
proxy until specific genetic markers become available
to treat genotypes rather than phenotypes.19 Others
have noted both the cultural and economic difficulties of transcending race once it has been accepted as
an explanatory factor in health outcomes and medical treatment. Duster notes that race as an “interim
solution” can still do much harm once given scientific
legitimacy.20 And, after noting the market incentives
leading to BiDil’s development,21 M. Gregg Bloche
argues that pharmaceutical firms with patent protection and regulatory approval for race-specific medicines have little incentive to sponsor research aimed
at finding the relevant genetic variations that would
obviate their previous research and devalue their intellectual property.22 Still others hypothesize that blacks
may have a genetic predisposition towards nitric oxide
deficiency that BiDil can address.23
Though these commentaries have provoked much
thought and discussion, they have largely not offered
a way to balance the pragmatic need to remain open
to potentially beneficial race-based medicines with
the need to minimize misleading conversations over
the genetic relevance of race. Is there a way for public
policy to take into account both the potential health
benefits of race-specific drugs and the attendant social
risks of geneticizing race?

Strict Scrutiny as a Regulatory Model
Despite ongoing investigations, BiDil’s effectiveness has not been linked to any genetic mechanism.
Remarkably, this did not prevent BiDil’s clinical trial
results and race-specific new drug application from
being interpreted as such. Steven Nissen, chair of
the FDA’s Cardiovascular and Renal Drugs Advisory
Committee, noted that the committee “us[ed] selfidentified race as a surrogate for genomics”24 when
they advised the FDA to approve BiDil’s race-specific
indication. This is only one example of how race as
an entrée to personalized medicines is becoming an
increasingly important consideration for federal regulators and why the FDA should prepare for what many
predict will be nothing short of a revolution in how we
approach health care.25
Currently, the FDA is without formal regulations or
procedures on how to review new drug applications
494

that target specific races beyond its traditional focus on
safety and efficacy, which are informed almost exclusively by clinical observations.26 This limited scope
may lead FDA officials to miss key social and ethical concerns that are not immediately demonstrable
in a clinical context — particularly when biotechnological innovations are involved. Take as an example
the FDA’s claim of regulatory authority over human
reproductive cloning.27 Ostensibly, if someone were
to attempt to clone a human being and demonstrated
that it could be performed safely and effectively, then
the FDA could approve the procedure. But, this
mandate does not necessarily address broader social
concerns over human reproductive cloning that exist
regardless of how safe or effective the procedure may
be. This is but one example of how biotechnology
requires a different sensitivity and sensibility because
of its unprecedented power to reshape basic human
relationships.
To understand how government can best negotiate this growing relationship between biotechnology
and race, constitutional law may offer a bit of guidance. In areas such as employment and education,
the United States Supreme Court has subjected the
state’s use and approval of racial categories, even for
benign purposes, to close examination. The application of this doctrine, known as strict scrutiny, came
out of a concern that federal and state governments
should neither create nor enforce illegitimate racial
classifications that may prove to be discriminatory or
unduly burdensome given the troublesome context of
American race relations. But, strict scrutiny also recognizes that some racial classifications may not only be
helpful, but essential to address ongoing inequalities.
Strict scrutiny as applied to race developed in the mid20th century as a function of the 14th Amendment’s
Equal Protection jurisprudence, which had an original
“pervading purpose…[to promote] the freedom of the
slave race, the security and establishment of freedom,
and the protection of [Blacks] from the oppressions of
those who had formerly exercised unlimited dominion
over him.”28 Though Equal Protection’s contours have
certainly changed since the Supreme Court offered
this language in 1873, it is important to note that this
idea of giving state-enforced racial categories an extra
level of scrutiny comes out of a longstanding commitment to racial equality and remedying past injustices.
Strict scrutiny does not hold that all racial classifications are impermissible per se, but only that they
should raise of our suspicion. In order to prevent
harmful or needless racial categorizations, strict scrutiny requires that when the state gets into the business of racially classifying individuals, these categories
should be “narrowly tailored to further compelling
journal of law, medicine & ethics
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state interests.”29 The state has the burden to demonstrate that its purpose is significant, non-discriminatory, and not exploitive. As the Supreme Court notes
in Richmond v. J. A. Croson, a case on the constitutionality of so called “minority business set asides,” the
purpose of strict scrutiny is to ensure that government
is “pursuing a goal important enough to warrant use of
a highly suspect tool.”30 This has led to a few remarkable balancing acts in terms of how public entities use
racial categories in their daily practices, even when
these practices may benefit minority populations. For
example, in the affirmative action context, universities
can take race into account when reviewing applications for the purpose of increasing racial diversity, but
may not use quotas.
As the gatekeeper standing between these powerful
technologies and their public impact, strict scrutiny
highlights a critical point that the FDA should consider when reviewing pharmacogenomic and other

apply to help ensure that race-specific drug claims
meet minorities’ needs in compelling and meaningful
ways and are not irresponsibly driven by commercial
desires. It can also help make sure that the individuals
that benefit the most from the drug continue to have
unimpeded access to it.
Since there is no precedent for how Equal Protection should inform the use of race in biomedicine, a
number of commentators have discussed its possible
relevance. Erik Lillquist and Charles Sullivan have
taken an exhaustive look at the legal relevance of this
issue, including how Equal Protection jurisprudence
might inform the development of race-based medicines and the use of racially exclusive clinical trials.32
Jonathan Kahn draws upon Equal Protection jurisprudence to advocate developing mechanisms within
clinical and biomedical research that resists conflating
genetic categories of population with social categories
of race while requiring a “tight fit” when such claims

Given the vigorous and unsettled debate concerning the genetic relevance
of race, the state has a strong interest in approving the use of race-specific
indications only when they are used cautiously, are supported by robust
scientific studies, and are not simply used as a convenient proxy.
personalized medicines: race is different. The Richmond Court aptly notes that “classifications based on
race carry a danger of stigmatic harm...[;] they may
in fact promote notions of racial inferiority and lead
to a politics of racial hostility.”31 The appropriate
use of race specific treatments must not only look at
“safety” and “efficacy” in a clinical or statistical sense,
but should be similarly rigorous in its examination of
social responsibility. Put differently, the use of race in
biomedicine should be held to a heightened standard
of proven efficacy and be narrowly tailored — that is,
used only when better proxies such as specific genetic
markers are not available. A key concern with the use
of racial indications in biomedicine, as with other categorizations in Constitutional law, is that they can be
both over and under inclusive. Racial indications may
be overinclusive, for example, by channeling too many
Blacks with heart failure towards BiDil when they
might fare better through other treatments. These
very same indications may also be underinclusive by
“missing” the substantial number of non-Black heart
failure patients who may benefit from BiDil in that
their doctors may not think to prescribe the medication to them. This additional layer of oversight can

are made.33 And Dorothy Roberts draws upon Equal
Protection norms to suggest a social justice framework that encourages researchers to use racial categories to combat health disparities, but resists its use as
a biological category to prevent dangerous racial ideas
from being reinforced.34
Each of these and other contributions are useful in
helping us think through the issues that arise when
race and biotechnological claims arise. They are united
by an effort to use Equal Protection norms and commitments to improve clinicians’ and researchers’ use
of race in their professional capacities. But perhaps
broader framings are similarly appropriate as strict
scrutiny is a regulatory approach that is designed to
examine whether the state is using racial categories
appropriately in light of constitutional mandates, not
only as an instrument that may suggest professional or
ethical guidelines. Thus, analogizing courts’ judicial
oversight to a normative scheme of clinical or research
best practices may not fully leverage strict scrutiny’s
broad regulatory spirit.
David Winickoff and I have drawn upon strict scrutiny to propose an oversight mechanism whereby
“race-specific indications should be rejected unless
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clinical trials can demonstrate convincingly that the
Conclusion
drugs are both better than existing treatments for a
Given the vigorous and unsettled debate concerning
specified group and no better than existing treatments
the genetic relevance of race, the state has a strong
for non-specified groups.”35 This approach is designed
interest in approving the use of race-specific indicato ensure that the evidence supporting race-specific
tions only when they are used cautiously, are supindications is robust and accessible
to the most appropriate groups.
Yet, another promising avenue to
The use of racial categories in medicine will
introduce a strict scrutiny analysis
require remarkable sensitivity and responsibility
may be through rethinking the role
of FDA advisory committees.
on the part of corporations, government,
FDA advisory committees are
clinicians, and consumers.
routinely used to give expert advice
on new drug applications to assist
the regulatory process and boost
the credibility of the FDA’s decision on whether to
ported by robust scientific studies, and are not simply
allow a drug to become publicly available.36 And, as
used as a convenient proxy. Like its role in Equal Prodemonstrated by the troubling “race as a surrogate
tection jurisprudence, this article proposes strict scrufor genomics” comments made by the chair of the
tiny as a regulatory guidepost for reviewing new drugs
FDA advisory committee that recommended BiDil’s
seeking race-specific labels to, as the Richmond Court
approval with a race-specific indication, the framing
notes, “smoke out illegitimate uses of race.”37 Whether
of these committees’ inquiry can either affirm or act as
BiDil itself could survive such scrutiny depends heava check against certain shortcomings within the narily upon how this additional form of oversight is develrow review of new drug applications that focus largely
oped and implemented. But, the take-home message
on safety and efficacy.
is that the use of racial categories in medicine will
While these committees are typically composed of
require remarkable sensitivity and responsibility on
physicians, scientists, and statisticians with expertise
the part of corporations, government, clinicians, and
relevant to the drug or device under review, an adviconsumers. As a result, it may very well be wise for
sory committee that uses a strict scrutiny framework to
us to have a deeper appreciation for how the battles
review any new drug that proposes a race-specific indiwaged to afford racial minorities Equal Protection of
cation could be a remarkable addition. Once a general
the laws can extend this same sentiment to medical
finding of safety and efficacy is made, this committee
research and health care.
would focus on whether a race specific indication is
appropriate by weighing the merits of approving the
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